The medical diagnostics company has achieved the final close of its series B round that was raised over three tranches from investors including biotech firm Qiagen.
US-based medical test developer Exosome Diagnostics has closed a $60m series B round featuring biotechnology company Qiagen.
Qiagen co-led the round’s $27m first tranche in 2014 alongside private equity firm Arcus Ventures. The first close also featured Tiger Partners, CD Ventures, Monashee Capital, NGN Capital and Forbion Capital Partners.
Exosome raised an extra $17.6m in September 2015 from Forbion, NGN, Arcus, CD and Tiger Management. Blue Ridge Capital participated in the final close, though further details concerning investors in…
